Immune, cellular, and microbiome supplement support is found here!
QTY - 30 Acid-Resistant Vegetarian Capsules
AB Companion is ideal for individuals seeking a well-rounded supplement to support a healthy balance of intestinal flora, cellular health, and immune health. It features four probiotic strains, including the extensively studied HN019 strain of Bifidobacterium lactis, plus Saccharomyces boulardii (Sb), a non-pathogenic yeast, to further complement healthy gastrointestinal ecology. Gastro-resistant, vegetarian capsules provide an innovative solution for targeted delivery of sensitive ingredients to the small intestine, as they alleviate exposure to the low pH environment of the stomach. Additionally, each capsule is sealed in a nitrogen-purged blister pack to provide protection from heat, moisture, and oxygen, factors known to compromise probiotic stability.*
- Balanced wellness pack
- Supports immune, gut, and cellular health
- Formulated with premier probiotic strains
- Nitrogen-purged blister pack
Journey into wellness with a balanced selection of supplements that support your immune, gut, and cellular health. Take advantage of premium probiotics that implement the HN019 strain of bifidobacterium lactis, all in a nitrogen-purged blister pack to preserve the integrity of the supplements.
- 30 capsules
- Serving size: One capsule
Diversity of gut microflora is characteristic of a healthy GI microbiome and contributes to overall health and vitality by promoting optimum digestion, assimilation, gut integrity, motility, and efficient removal of toxins and wastes. Many internal and external influences, including stress, a poor diet, food sensitivities, medication, environmental factors, and certain disease conditions, can impact the microbial balance within this fine-tuned community. Their impact can allow potential colonization by pathogenic organisms and disrupt a healthy balance, which can result in adverse effects ranging from GI symptoms to impaired immune response.[1-3] Probiotics are part of the key to promoting the optimal balance of the microbiome, whether they originate from dietary sources or from supplements. Probiotic yeasts, such as Saccharomyces boulardii, also play a role in gut ecology by supporting intestinal barrier function and integrity.*
Careful selection of organisms is another way Bock Nutritionals helps ensure stability and digestive survivability. To further support resistance to low pH and the delivery of microorganisms to the small intestines, Bock Nutritionals encapsulates the ingredients in gastro-resistant DRcaps™. These specially designed, innovative capsules help slow exposure of actives to stomach acid to promote a more targeted release.*
Suggested Dosage - Take one capsule daily, or as directed by your healthcare practitioner. Consult your healthcare practitioner prior to use. Individuals taking medication should discuss potential interactions with their healthcare practitioner.
Serving Size - 1 Capsule
Servings Per Container - 30
|Ingredients||Amount Per Serving||%DV|
|Saccharomyces boulardii||250 mg ( 5 Billion CFU†)||**|
Lactobacillus acidophilus La-14®
Bifidobacterium longum Bl-05™
Lactobacillus plantarum Lp-115®
|74 mg (5 Billion CFU†)||**|
HOWARU® Bifido (Bifidobacterium lactis HN019®)
|50 mg (15 Billion CFU†)||**|
Other Ingredients - Capsule (hypromellose, gellan gum, and water), microcrystalline cellulose, hydroxypropyl cellulose, ascorbyl palmitate, and silica.
Does Not Contain
Wheat, gluten, soy, animal or dairy products, fish, shellfish, peanuts, tree nuts, egg, ingredients derived from genetically modified organisms (GMOs), artificial colors, artificial sweeteners, or artificial preservatives.
1. Heiman ML, Greenway FL. A healthy gastrointestinal microbiome is dependent on dietary diversity. Mol Metab. 2016 Mar 5;5(5):317-20. [PMID: 27110483]
2. Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. Genome Med. 2016 Apr 27;8(1):51. [PMID: 27122046]
3. Xu Z, Knight R. Dietary effects on human gut microbiome diversity. Br J Nutr. 2015 Jan;113 Suppl:S1-5. [PMID: 25498959]
4. Grimm V, Riedel CU. Manipulation of the microbiota using probiotics. Adv Exp Med Biol. 2016;902:109-17. [PMID: 27161354]
5. Gopal P, Prasad J, Gill HS. Effects of the consumption of Bifidobacterium lactis HN019 (DR10TM) and galacto-oligosaccharides on the microflora of the gastrointestinal tract in human
subjects. Nutr Res. 2003;23:1313-28. https://www.optibacprobiotics.co.uk/uploads/gopal-2003-effect-of-HN019-and-GOS-on-microflora-in-GIT-in-humans.pdf. Accessed January 9, 2018.
6. Danisco. Clinical study bibliography & abstracts. HOWARU® Bifido. http://www.danisco.com/product-range/probiotics/howarur-premium-probiotics/howarur-bifido-probiotics/howarurbifido-clinical-studies/#c21397. Accessed January 9, 2018.
7. Waller PA, Gopal PK, Leyer GJ, et al. Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scand J
Gastroenterol. 2011 Sep;46(9):1057-64. [PMID: 21663486]
8. Ahmed M, Prasad J, Gill H, et al. Impact of consumption of different levels of Bifidobacterium lactis HN019 on the intestinal microflora of elderly human subjects. J Nutr Health Aging.
2007 Jan-Feb;11(1):26-31. [PMID: 17315077]
9. Greene JD, Klaenhammer TR. Factors involved in adherence of lactobacilli to human Caco-2 cells. Appl Environ Microbiol. 1994 Dec;60(12):4487-94. [PMID: 7811085]
10.Kleeman EG, Klaenhammer TR. Adherence of Lactobacillus species to human fetal intestinal cells. J Dairy Sci. 1982 Nov;65(11):2063-69. [PMID: 7153393].
11. Collado MC, Meriluoto J, Salminen S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Lett Appl Microbiol. 2007 Oct;45(4):454-60. [PMID:
12. Ding WK, Shah NP. Acid, bile, and heat tolerance of free and microencapsulated probiotic bacteria. J Food Sci. 2007 Nov;72(9):M446-50. [PMID: 18034741]
13. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010 May 14;16(18):2202-22. [PMID: 20458757]
14. Riaz M, Alam S, Malik A, et al. Efficacy and safety of Saccharomyces boulardii in acute childhood diarrhea: a double blind randomised controlled trial. Indian J Pediatr. 2012
Apr;79(4):478-82. [PMID: 21997865]
15. Vandenplas Y, Brunser O, Szajewska H. Saccharomyces boulardii in childhood. Eur J Pediatr. 2009 Mar;168(3):253-65. [PMID: 19096876]
16. Can M, Besirbellioglu BA, Avci IY, et al. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. Med Sci Monit. 2006
Apr;12(4):PI19-22. [PMID: 16572062]
17. Castagliuolo I, Riegler MF, Valenick L, et al. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun. 1999
Jan;67(1):302-7. [PMID: 9864230]
18. Im E, Pothoulakis C. Recent advances in Saccharomyces boulardii research [in French]. Gastroenterol Clin Biol. 2010 Sep;34 Suppl 1:S62-70. Review. [PMID: 20889007]
19. Krasowska A, Murzyn A, Dyjankiewicz A, et al. The antagonistic effect of Saccharomyces boulardii on Candida albicans filamentation, adhesion and biofilm formation. FEMS Yeast
Res. 2009 Dec;9(8):1312-21. [PMID: 19732158]
20. Natural Standard Database. Saccharomyces Boulardii Monograph. http://naturaldatabase.therapeuticresearch.com/nd/Search.aspx?cs=&s=ND&pt=100&id=332&ds=. Accessed
January 9, 2018.
21. Buts JP, Bernasconi P, Vaerman JP, et al. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig
Dis Sci. 1990 Feb;35(2):251-6. [PMID: 2302983]
22. Dahan S, Dalmasso G, Imbert V, et al. Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells. Infect Immun. 2003
Feb;71(2):766-73. [PMID: 12540556]
23. Pothoulakis C. Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii. Aliment Pharmacol Ther. 2009 Oct 15;30(8):826-33. Review. [PMID: 19706150]
24. Schneider SM, Girard-Pipau F, Filippi J, et al. Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition. World J
Gastroenterol. 2005 Oct 21;11(39):6165-9. [PMID: 16273644]
25. Lewis K, Lutgendorff F, Phan V, et al. Enhanced translocation of bacteria across metabolically stressed epithelia is reduced by butyrate. Inflamm Bowel Dis. 2010 Jul;16(7):1138-48.